Journal Article

CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study

Manabe, Yusuke, Shiroyama, Takayuki, Kumanogoh, Atsushi, Kuroda, Etsushi, Miyake, Kotaro, Temizoz, Burcu, Hirata, Haruhiko, Takeda, Yoshito, Nishida, Sumiyuki, Shibahara, Takayuki, Mizuno, Yumiko, Yagita, Mayu, Kimura, Keiko, Hamaguchi, Masanari, Otsuka, Tomoyuki, Kida, Hiroshi, Ishii, Ken J.

2022

Overview

Background Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) (K3)—a novel synthetic single-stranded DNA immune adjuvant for cancer immunotherapy—induces a potential Th1-type immune response against cancer cells. We conducted a phase I study of CpG ODN (K3) in patients with lung cancer to assess its safety and patients’ immune responses. Methods The primary endpoint was the proportion of dose-limiting toxicities (DLTs) at each dose level. Secondary endpoints included safety profile, an immune response, including dynamic changes in immune cell and cytokine production, and progression-free survival (PFS). In a 3 + 3 dose-escalation design, the dosage levels for CpG ODN (K3) were 5 or 10 mg/body via subcutaneous injection and 0.2 mg/kg via intravenous administration on days 1, 8, 15, and 29. Results Nine patients (eight non-small-cell lung cancer; one small-cell lung cancer) were enrolled. We found no DLTs at any dose level and observed no serious treatment-related adverse events. The median observation period after registration was 55 days (range: 46–181 days). Serum IFN-α2 levels, but not inflammatory cytokines, increased in six patients after the third administration of CpG ODN (K3) (mean value: from 2.67 pg/mL to 3.61 pg/mL after 24 hours). Serum IFN-γ (mean value, from 9.07 pg/mL to 12.7 pg/m after 24 hours) and CXCL10 levels (mean value, from 351 pg/mL to 676 pg/mL after 24 hours) also increased in eight patients after the third administration. During the treatment course, the percentage of T-bet-expressing CD8 + T cells gradually increased (mean, 49.8% at baseline and 59.1% at day 29, p  = 0.0273). Interestingly, both T-bet-expressing effector memory (mean, 52.7% at baseline and 63.7% at day 29, p  = 0.0195) and terminally differentiated effector memory (mean, 82.3% at baseline and 90.0% at day 29, p  = 0.0039) CD8 + T cells significantly increased. The median PFS was 398 days. Conclusions This is the first clinical study showing that CpG ODN (K3) activated innate immunity and elicited Th1-type adaptive immune response and cytotoxic activity in cancer patients. CpG ODN (K3) was well tolerated at the dose settings tested, although the maximum tolerated dose was not determined. Trial registration UMIN-CTR number 000023276. Registered 1 September 2016, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000026649

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adaptive immunity / Agonists / Antibodies / Antigens / Biomedical and Life Sciences / Biomedicine / Blood / Cancer immunotherapy / Cancer Research / Cancer therapies / Care and treatment / CD8 antigen / Chemotherapy / Cloning / CXCL10 protein / Cytokines / Cytology / Cytosine / Cytosine-phosphate-guanine oligodeoxynucleotide / Cytotoxicity / Dendritic cells / Dose-limiting toxicity / Genetic aspects / Guanine / Health aspects / Health Promotion and Disease Prevention / Immune response / Immunology / Immunotherapy / Inflammation / Innate immunity / Intravenous administration / Lung cancer / Lymphocytes T / Malaria / Medical prognosis / Medicine/Public Health / Non-small cell lung carcinoma / Oligodeoxynucleotides / Oligonucleotides / Oncology / Patient outcomes / Patients / Registration / Research Article / Single-stranded DNA / Software / Surgical Oncology / Toll-like receptor 9 agonist / Toll-like receptors / Vaccines / γ-Interferon